Inhibition	NN
of	IN
the	DT
KCa3	NN
.1	CD
Channel	NNP
Alleviates	VBZ
Established	VBN
Pulmonary	JJ
Fibrosis	NN
in	IN
a	DT
Large	JJ
Animal	NNP
Model	NNP
.	.

UNASSIGNED	NNP
:	:
Idiopathic	JJ
pulmonary	JJ
fibrosis	NN
is	VBZ
a	DT
chronic	JJ
progressive	JJ
disease	NN
of	IN
increasing	VBG
prevalence	NN
marked	VBN
by	IN
poor	JJ
prognosis	NN
and	CC
limited	JJ
treatment	NN
options	NNS
.	.

Ca2	NN
+	CC
-	:
activated	VBN
KCa3	NN
.1	CD
potassium	NN
channels	NNS
have	VBP
been	VBN
shown	VBN
to	TO
play	VB
a	DT
key	JJ
role	NN
in	IN
the	DT
aberrant	JJ
activation	NN
and	CC
responses	NNS
to	TO
injury	NN
in	IN
both	CC
epithelial	JJ
cells	NNS
and	CC
fibroblasts	NNS
,	,
both	CC
considered	VBN
key	JJ
drivers	NNS
in	IN
the	DT
fibrotic	JJ
process	NN
of	IN
IPF	NN
.	.

Pharmacological	JJ
inhibition	NN
of	IN
IPF-derived	JJ
fibroblasts	NNS
is	VBZ
able	JJ
to	TO
somewhat	RB
prevent	VB
TGF-band	JJ
bFGF-dependent	JJ
profibrotic	JJ
responses	NNS
.	.

In	IN
the	DT
current	JJ
study	NN
,	,
we	PRP
investigated	VBD
whether	IN
blockade	NN
of	IN
the	DT
KCa3	NN
.1	CD
ion	NN
channel	NN
in-vivo	JJ
with	IN
a	DT
selective	JJ
inhibitor	NN
,	,
Senicapoc	NN
,	,
was	VBD
able	JJ
to	TO
attenuate	VB
both	CC
histological	JJ
and	CC
physiological	JJ
outcomes	NNS
of	IN
early	JJ
fibrosis	NN
in	IN
our	PRP$
large	JJ
animal	NN
(	(
sheep	NN
)	)
model	NN
for	IN
pulmonary	JJ
fibrosis	NN
.	.

We	PRP
also	RB
determined	VBD
whether	IN
treatment	NN
was	VBD
targeting	VBG
the	DT
pro-fibrotic	JJ
activity	NN
of	IN
sheep	NN
lung	NN
fibroblasts	NNS
.	.

Senicapoc	NN
was	VBD
administered	VBN
in	IN
established	JJ
fibrosis	NN
,	,
at	IN
2	CD
weeks	NNS
after	IN
bleomycin	NN
instillation	NN
,	,
and	CC
drug	NN
efficacy	NN
was	VBD
assessed	VBN
4	CD
weeks	NNS
after	IN
treatment	NN
.	.

Treatment	NN
with	IN
Senicapoc	NN
improved	VBD
pre-established	JJ
bleomycin-induced	JJ
changes	NNS
compared	VBN
to	TO
vehicle	NN
control	NN
,	,
leading	VBG
to	TO
improved	VBN
lung	NN
compliance	NN
,	,
reduced	VBD
extracellular	JJ
matrix	NN
and	CC
collagen	NN
deposition	NN
,	,
and	CC
a	DT
reduction	NN
in	IN
both	CC
alpha	NN
smooth	JJ
muscle	NN
actin	NN
expression	NN
and	CC
proliferating	VBG
cells	NNS
,	,
both	DT
in-vivo	JJ
and	CC
in-vitro	FW
.	.

These	DT
studies	NNS
show	VBP
that	IN
inhibiting	VBG
the	DT
KCa3	NN
.1	CD
ion	NN
channel	NN
is	VBZ
able	JJ
to	TO
attenuate	VB
the	DT
early	JJ
fibrogenic	JJ
phase	NN
of	IN
bleomycin-dependent	JJ
fibrosis	NN
and	CC
inhibits	VBZ
pro-fibrotic	JJ
behaviour	NN
of	IN
primary	JJ
sheep	NN
lung	NN
fibroblasts	NNS
.	.

This	DT
supports	VBZ
the	DT
previous	JJ
research	NN
conducted	VBN
in	IN
human	JJ
IPF-derived	JJ
fibroblasts	NNS
and	CC
suggests	VBZ
that	IN
inhibiting	VBG
Kca3	JJ
.1	NN
signalling	NN
may	MD
provide	VB
a	DT
novel	JJ
therapeutic	JJ
approach	NN
for	IN
IPF	NN
.	.

